戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              HDT as consolidation therapy for relapsed ESFT seems to
2                                              HDT was associated with slightly higher 1-year mean grad
3                                              HDT/AHCT was carried out according to institutional stan
4                The study suggests that acute HDT can reduce ICC, altering sympathovagal balance and c
5 stic model provides a basis for risk-adapted HDT.
6 py with ICE with the intent of administering HDT/ASCT to those patients with chemosensitive disease w
7 emotherapy, with the intent of administering HDT/ASCT to those with chemosensitive disease.
8                                        After HDT, hematopoietic recovery to critical levels of granul
9 tiparameter flow cytometry at day +100 after HDT/ASCT (hazard ratio 8.0; P = .005) were the only inde
10 ries of 241 patients in CR at day +100 after HDT/ASCT who were enrolled in the Spanish GEM2000 (n = 1
11 n whom cytogenetic data were available after HDT.
12 th improved survival and local control after HDT, local radiotherapy (21 Gy), and immunotherapy.
13    All patients who achieved BCR or CR after HDT-ASCT (ACR) were identified.
14 fore could optimise the chance of cure after HDT/ASCT.
15 ents with MDS-CAs, its detection early after HDT was associated with longer time interval from diagno
16 nts in CR at risk of early progression after HDT/ASCT in whom novel treatments should be investigated
17 older age, and lower platelet recovery after HDT; persistent MDS-CAs were predicted by CD34 yield of
18                              Rituximab after HDT and HCT is feasible, and these phase 2 data support
19  patients who experienced relapse soon after HDT suggest that more aggressive induction chemotherapy
20 ML, at a median follow-up of 5.9 years after HDT.
21 sfully correlated with the amount of DNA and HDT molecules immobilized on the LSPR sensor surface.
22          Therefore, dose-dense induction and HDT/ASCT are a rational up-front strategy in transplanta
23 n the ICP P2/P1 ratio when comparing pre and HDT at -6o (p = 0.004) and a trend toward elevation at -
24                                  By applying HDT and a drug repurposing approach, we demonstrate that
25 n response rates between the two study arms (HDT, n = 261 patients; SDT, n = 255 patients).
26  required to analyze the safety of COX-2i as HDT in patients with tuberculosis.
27 ttering from chemisorption of the Lewis base HDT on the atom-scale junction caused a normalized imped
28 d after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria.
29 nts received reinduction chemotherapy before HDT and HSCR.
30 We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced fu
31 els of abnormal cells can be detected before HDT and may predict which patients are at increased risk
32 of clonally abnormal cells were found before HDT in 20 of 20 tMDS/sAML patients screened, compared wi
33        An intensive induction regimen before HDT and ASCT was not associated with improved survival a
34 oma should be a negative FDG-PET scan before HDT/ASCT.
35 tic component of CAM was predominant in both HDT, and brain oscillations were reduced in most tests.
36 ntense second-line chemotherapy, followed by HDT and ASCT, are reported.
37             Dose-dense induction followed by HDT/ASCT was well tolerated and led to long-term PFS in
38 ezomib/thalidomide/dexamethasone followed by HDT/ASCT; n = 276).
39 , adriamycin, and dexamethasone) followed by HDT/ASCT; n = 319] and GEM2005<65y (randomized induction
40  HD-RIT and 53% and 29%, respectively, for C-HDT.
41 the HD-RIT group and.086 at 7 years in the C-HDT group.
42 as 3.7% in the HD-RIT group and 11% in the C-HDT group.
43 n = 27) or conventional high-dose therapy (C-HDT) (n = 98) and autologous hematopoietic stem cell tra
44         HD-RIT may improve outcomes versus C-HDT in patients with relapsed FL.
45                      Patients treated with C-HDT received total body irradiation plus chemotherapy (7
46  0.5, P =.03) versus patients treated with C-HDT.
47 sease (HD) with high-dose chemoradiotherapy (HDT) and autologous stem cell transplantation (ASCT) res
48 o had undergone high-dose chemoradiotherapy (HDT) with autologous stem cell rescue for Hodgkin's dise
49                 High-dose chemoradiotherapy (HDT) with autologous stem cell transplantation (ASCT) is
50 olidated by up-front high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) in
51 one or two cycles of high-dose chemotherapy (HDT) followed by autologous HSCR.
52                      High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is
53 rove PFS after high-dose radio-chemotherapy (HDT) and ASCT.
54 from the pre-HDTBR measured in the 6 degrees HDT posture, with a mean (95% confidence interval) incre
55 n interactions is vital to rationally design HDT strategies.
56 d with and without leg muscle loading during HDT in healthy human subjects, both at rest and during r
57                   Loading leg muscles during HDT at rest led to significantly higher values of arteri
58 y modulates cardiovascular regulation during HDT.
59        Four patients who completed the first HDT course did not complete the second, and there were t
60   Treatment-related mortality with the first HDT cycle was 2% in younger and 8% among older subjects,
61 uivalent to a population fluctuation of five HDT molecules.
62                                    Following HDT-ASCT, effector CD4(+) and CD8(+) immunophenotypes ma
63 eceptor (CAR) T cells administered following HDT-ASCT.
64 ab vedotin maintenance was allowed following HDT/AHCT.
65                 19-28z CAR T cells following HDT-ASCT were associated with a high incidence of revers
66 rtion of patients who achieve a CR following HDT, although other biologic characteristics of the tumo
67 9.8 +/- 4.6 for sitting, and 6.6 +/- 2.5 for HDT.
68  Mtb host-pathogen interactions as basis for HDT strategies; and (ii) discuss the components and util
69  every 12 h, day 1) before consideration for HDT/ASCT.
70 we propose the AhR as a potential target for HDT in TB in adjunct to canonical chemotherapy.
71 mpedance was measured while hexadecanethiol (HDT) was chemisorbed onto the atom-scale junction.
72 ) template (T30), spaced with hexanedithiol (HDT) in a molar ratio of 1:1.
73 ting, or HDT (P >/= 0.11), except for IOP in HDT (P = 0.04).
74  systems pharmacology (QSP) models to inform HDT strategies.
75                                The 30-minute HDT protocol was performed at -6o and - 15o.
76 ies heavily on coal power, so impacts of new HDT technologies depend on the timing of their introduct
77                   RNA sequencing analysis of HDT-treated lung and granuloma tissues implicates up-reg
78     Patients then received tandem courses of HDT/SCR, 4 to 6 weeks apart.
79         Four patients received two cycles of HDT and HSCR.
80  12 years) were assessable, and 70 cycles of HDT/SCR were completed.
81 in saturation levels persisted after 57 d of HDT bed rest (+13.5%, P = 0.026), suggesting that long-t
82                    In females, 6 and 57 d of HDT bed rest did not significantly change serum iron, tr
83 , P = 0.009) increased in males after 6 d of HDT bed rest, as well as serum hepcidin concentrations (
84 imed to investigate the immediate effects of HDT at -6o and - 15o on ICC, CAM and brain oscillations
85 nistic nature of the different mechanisms of HDT over short timescales means their contribution to ba
86 or understanding the evolutionary origins of HDT.
87 significantly, justifying further pursuit of HDT, especially toward curing non-triangle up13 MM.
88                                   The use of HDT with ABMT has been shown to improve survival in mult
89 ts who lose their CR status within 1 year of HDT/ASCT (unsustained CR) have poor prognosis.
90                     Clinical utility data on HDT benefit in these patients and other special subsets
91 o 1998, 218 patients with HL were treated on HDT with ASCR salvage protocols.
92 in ICP, IOP, or TLCPD in supine, sitting, or HDT (P >/= 0.11), except for IOP in HDT (P = 0.04).
93                         Among 1028 patients, HDT was performed in 406 patients (39.5%).
94 s would not have participated in the pivotal HDT trials.
95 occurred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted.
96 rapy 2 and Total Therapy 3 that applied post-HDT consolidation chemotherapy (suggesting possible post
97 ation chemotherapy (suggesting possible post-HDT damage).
98 d site radiation, and 13 (33%) received post-HDT/AHCT brentuximab vedotin maintenance.
99 mg/L, C-reactive protein </= 4 mg/L, and pre-HDT standard chemotherapy </= 12 months.
100 DT platelet count (likely resulting from pre-HDT damage), whereas late-onset MDS-CAs were noted among
101 ger time interval from diagnosis and low pre-HDT platelet count (likely resulting from pre-HDT damage
102                                 No other pre-HDT-ASCT risk factors significantly impacted PFS or OS.
103 ents transplanted with negative FDG-PET, pre-HDT/ASCT after 1 or 2 SLT programs, had an EFS of > 80%,
104 ents proceeded to HDT/AHCT, two received pre-HDT/AHCT involved site radiation, and 13 (33%) received
105                            Several promising HDT candidates are being evaluated, but major advancemen
106 nts treated with RHCVAD (n = 83, 50%), RCHOP+HDT/ASCR (n = 34, 20%), RCHOP (n = 29, 17%), or RHCVAD+H
107 l survival (OS) between the RHCVAD and RCHOP+HDT/ASCR (P = .98).
108       RCHOP was inferior to RHCVAD and RCHOP+HDT/ASCR, which had similar PFS and OS.
109 stine, adriamycin, and dexamethasone), RCHOP+HDT/ASCR (rituximab, cyclophosphamide, doxorubicin, vinc
110 eatment as per protocol proceeded to receive HDT/ASCT.
111 tients) subtypes of B-cell lymphoma received HDT followed by a purged autologous graft.
112         Because all 13 patients who received HDT also had responsive relapse, we performed a multivar
113 , 0.29; 95% CI, 0.13 to 0.66), and receiving HDT (relative risk, 0.26; 95% CI, 0.08 to 0.85).
114 s (high-dose therapy) with stem-cell rescue (HDT/SCR) in rapid sequence.
115 n = 34, 20%), RCHOP (n = 29, 17%), or RHCVAD+HDT/ASCR (n = 21, 13%).
116 therapy/autologous stem cell rescue), RHCVAD+HDT/ASCR, or RCHOP.
117                              CR and a second HDT cycle applied within 6 months both extended event-fr
118 nd older subjects with both first and second HDT.
119         We use a bottom-up model to simulate HDT energy consumption and CO(2) emissions through 2050.
120 o significant difference in response to SLT, HDT, event-free or overall survival based on the cell of
121                                Specifically, HDT targets host-encoded factors required for pathogen r
122                  Patients underwent standard HDT-ASCT followed by 19-28z CAR T cells on days +2 and +
123 nts for most deaths among patients surviving HDT and ASCR.
124                                     A tandem HDT/SCR regimen for high-risk neuroblastoma is a feasibl
125 ve patients receiving melphalan-based tandem HDT.
126 an macrophages and their potential as new TB HDT therapeutic targets.
127 more contemporary high deployment technique (HDT).
128                     Our results suggest that HDT with HSCR is an effective treatment for patients wit
129                                          The HDT and SDT regimens used in S9321 yielded comparable re
130                                          The HDT-NTD requires an additional A2 acidic tract C-termina
131  and OS durations did not differ between the HDT and SDT arms, with 7-year estimates of PFS of 17% an
132 le difference in Anopheles catch between the HDT compared with the HLC (RR = 0.85, P = 0.508).
133 vercome by incorporating novel agents in the HDT/ASCT setting.
134 ) corresponding to three orientations of the HDT moiety.
135 ) corresponding to three orientations of the HDT moiety.
136 l: 1.50-9.30) whereas the sensitivity of the HDT was only greater than the Suna trap when mosquito nu
137 le interval: 2.00-3.85).We conclude that the HDT is an effective sampling device for outdoor host see
138 improved by adjunct host-directed therapies (HDT) targeting host responses.
139 r research on novel host-directed therapies (HDT).
140                       Host-directed therapy (HDT) has emerged as a promising adjunct to current treat
141 rmine eligibility for HER2-directed therapy (HDT) in breast cancer.
142                       Host-directed therapy (HDT) is an emerging approach to overcome antimicrobial r
143                       Host-directed therapy (HDT) is an emerging concept currently explored as an adj
144                       Host-directed therapy (HDT) offers a novel strategy with mechanisms that includ
145 tudy of PIXY321 following high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) w
146 ficacy and toxicity after high-dose therapy (HDT) and autologous hematopoietic cell transplantation (
147 therapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to
148                           High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) are
149 atopoietic cell-supported high-dose therapy (HDT) effected higher complete response rates and extende
150                           High-dose therapy (HDT) has increased complete remission (CR) rates and sur
151 me to standard treatment, high-dose therapy (HDT) has usually been limited to patients up to 65 years
152 d the relative benefit of high-dose therapy (HDT) is controversial.
153 oma who were eligible for high-dose therapy (HDT) were enrolled onto the trial.
154 lating factors (CSFs), or high-dose therapy (HDT) with autologous bone marrow support (ABMT).
155 ved response criteria for high-dose therapy (HDT), and had no resection before induction were include
156 3,077 patients undergoing high-dose therapy (HDT).
157 male participants exposed to head-down tilt (HDT) bed rest, the reference ground-based model of micro
158 pine, sitting, and 9 degrees head-down tilt (HDT) positions.
159 cts and the most used one is head-down tilt (HDT).
160 e, sitting, and in 9 degrees head-down tilt (HDT).
161 valuated such effects during head-down tilt (HDT).
162 iciently bridge patients with rel/ref cHL to HDT/AHCT.
163 n, longer time interval from MM diagnosis to HDT, older age, and lower platelet recovery after HDT; p
164 ville score of 1 or 2) proceeded directly to HDT/ASCT; those with persistent abnormalities on PET rec
165 hy male participants who were all exposed to HDT bed rest for 60 d.
166       Thirty-six (95%) patients proceeded to HDT/AHCT, two received pre-HDT/AHCT involved site radiat
167 CI 13-40) were PET-negative and proceeded to HDT/ASCT.
168 evidence of disease progression proceeded to HDT/ASCT; those with progressive disease were study fail
169 29 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET accordi
170 termine whether the depth of the response to HDT-ASCT leads to an improvement in time to progression
171                     Horizontal DNA transfer (HDT) is a pervasive mechanism of diversification in many
172 therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relapsed or refractory Hodgk
173 y with autologous stem-cell transplantation (HDT-ASCT) is now almost standard therapy for many patien
174 py and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primar
175 y plus autologous stem-cell transplantation (HDT-ASCT).
176 tologous hematopoietic cell transplantation (HDT/AHCT).
177 herapy/autologous stem cell transplantation (HDT/ASCT) and novel agents has significantly improved su
178 herapy/autologous stem cell transplantation (HDT/ASCT) is a surrogate for prolonged survival in multi
179  sampling efficiency of the host decoy trap (HDT) with the human landing catch (HLC) and Suna trap in
180                                      TreoMel-HDT may be of benefit for children age < 14 years.
181 domly assigned to receive additional TreoMel-HDT or no further treatment (control).
182  with very high-risk EWS, additional TreoMel-HDT was of no benefit for the entire cohort of patients.
183 ignificant difference in EFS between TreoMel-HDT and control in the adaptive design (hazard ratio [HR
184 nd melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic
185 tients age < 14 years benefited from TreoMel-HDT with a 3-years EFS of 39.3% (95% CI, 20.4 to 75.8%)
186  was 20.9% (95% CI, 11.5 to 37.9) in TreoMel-HDT and 19.2% (95% CI, 10.8 to 34.4) in control patients
187 e randomly assigned, and 55 received TreoMel-HDT.
188                   Males treated with TreoMel-HDT had better EFS compared with controls: median 1.0 ye
189 t peripheral blood stem cells to support two HDT cycles (CD34 > 5 x 10(6)/kg) were available in 83% o
190 e or non-Hodgkin's lymphoma (NHL) undergoing HDT and ABMT received PIXY321 post-ABMT in doses that ra
191                          Patients undergoing HDT with stem cell rescue are at an increased risk of t-
192 ly descended bacterial population undergoing HDT through transmission of mobile genetic elements (MGE
193                     A total of 115 underwent HDT/ASCT, with 90 in complete remission at 3 months post
194 nt in the majority of patients who underwent HDT and ABMT for lymphoid malignancies.
195 ifying functional host targets for pan-viral HDT.
196 relatively good outcome can be achieved with HDT and PSCT, even in patients with a significant marrow
197 on, patients proceeded to consolidation with HDT/ASCT.
198 e patient (0.2%) had valve embolization with HDT (P=0.216).
199 ay permanent pacemaker rates were lower with HDT (5.5% versus 13.1%; P<0.001), as were rates of compl
200 her major responses were primarily seen with HDT-ASCT, but insights into the biology of MM have led t
201 coronary cusp was significantly smaller with HDT compared with conventional technique (1.5 1.6 versus

 
Page Top